Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals
with generic competitor.
The pharmacy benefits manager, which has major operations in Whitestown, said fourth quarter profit rose 24 percent.
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
Obama, seeking to break an impasse over health-care legislation, proposes a plan that includes the first Medicare tax on unearned
income such as capital gains and higher fees on drugmakers.
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
Pharmacy giant CVS will pay $1.95 million and verify that all of its pharmacists are licensed in Indiana to settle a state
complaint that pharmacists with expired licenses dispensed prescriptions for several years at two of its drugstores.
Mississippi will receive $18.5 million from Indianapolis-based drugmaker Eli Lilly and Co. as part of a settlement over claims
the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat.
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
Analysts worry about dive in already paltry sales of new blood thinner Effient
Drug distribution firm that acquired former WellPoint subsidiary plans to consolidate specialty pharmacy work at local
airport facility.
Express Scripts Inc. on the west side of Indianapolis and Zipp Speed Weaponry in Speedway are scheduled Wednesday afternoon
to announce the
creation of hundreds of new jobs.
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
